Clinical Trials Logo

Nosocomial Infections clinical trials

View clinical trials related to Nosocomial Infections.

Filter by:

NCT ID: NCT00151606 Completed - Clinical trials for Nosocomial Infections

Comparison of Two Protocols to Prevent the Acquisition of Methicillin-Resistant Staphylococcus Aureus.

Start date: December 2002
Phase: N/A
Study type: Interventional

Nosocomial infections is a major problem in intensive care units due to both growing incidence and pathogens implicated which become increasingly resistant to antibiotics. According to the Center for Disease Control (USA), Staphylococcus aureus is responsible for approximately 10% of cases. In Europe, 79% of the S.aureus strains are resistant to methicillin, a routinely used antibiotic. Recommendations for the prevention of transmission of these resistant bacteria are rarely based on controlled trials. Therefore the aim of our study is to evaluate two protocols to prevent the acquisition of methicillin-resistant S. Aureus in intensive care units: either a reinforced isolation precautions protocol or a standard precautions protocol.

NCT ID: NCT00122057 Completed - Clinical trials for Respiratory Tract Diseases

Impact of Antibiotic Treatment on Outcome in Patients With Ventilator-Associated Tracheobronchitis

Start date: June 2005
Phase: N/A
Study type: Interventional

The aim of this study is to determine whether antibiotic treatment could reduce mechanical ventilation duration in patients with nosocomial tracheobronchitis acquired under mechanical ventilation.

NCT ID: NCT00113191 Completed - Sepsis Clinical Trials

Safety and Efficacy of Veronate® Versus Placebo in Preventing Nosocomial Staphylococcal Sepsis in Premature Infants

Start date: May 2004
Phase: N/A
Study type: Interventional

The purpose of this study is to show whether Veronate, a donor-selected staphylococcal human immune globulin intravenous (IGIV), can prevent an infection in the blood caused by staphylococcal bacteria in premature babies weighing between 500 and 1250 grams at birth. Babies are enrolled between Day of Life 3 and 5. Babies are randomized to either Veronate or placebo (50-50 chance of either). Babies can receive up to 4 doses of the study drug on Study Days 1, 3, 8 and 15 and are followed until Study Day 70 or discharge from the hospital.